期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

磺脲类药物代谢及其药物基因组学研究进展 被引量：4

Recent progress in studies on metabolism and pharmacogenomics of sulfonylurea agents
原文传递
导出
摘要 磺脲类药物作为胰岛素促泌剂，是过去50年里2型糖尿病药物治疗领域的一个里程碑。尽管磺脲类药物可有效地降低血糖，但其药物疗效及不良反应具有个体差异，这可能与其相关的基因有关，现就磺脲类药物代谢及其药物基因组学的研究进展作简要综述。 The sulfonylureas as insulin seeretagogues, have tbrmed a cornerstone ol pharmaeotherapy tor type 2 diabetes over 50 years. Although sulfonylureas are effective antihyperglyeemic agents, individual, variability exists in drug response （ i. e. , phannacodynamics） and adverse effects which may be related to some genes. This article mainly reviews the advance of recent studies about drug metabolism and pharmaeogenomics of sulfonylureas.
作者 李青 胡承 贾伟平
机构地区 上海交通大学附属第六人民医院内分泌代谢科
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2012年第10期866-868,共3页 Chinese Journal of Endocrinology and Metabolism
关键词 磺脲类药物 基因 药物基因组学 糖尿病 2型 Snlflmylureas agents Gene Pharmaeogenomies Diabetes mellitus, type 2
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献39

  • 1Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet, 2005, 365: 1333- 1346.
  • 2Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia, 2003,46 : 3-19.
  • 3Fukuen S, Iwaki M, Yasui A, et al. Sulfonylurea agents exhibit pemxisome ptx31iferator-activated receptor gamma agonistic activity, J Biol Chem, 2005,280:23653-23659.
  • 4Pearson ER. Pharmacogenetics and future strategies in treating hyperglycaemia in diabetes. Front Biosci, 2009,14:43484362.
  • 5Pearson ER, Donnelly LA, Kimber C, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas--a GoDARTs study. Diabetes, 2007,56:2178-2182.
  • 6Beeker ML, Visser LE, Trienekens PH, et al. Cytochrome P450 2C9 * 2 and * 3 polymovphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmaeol Ther, 2008,83,288-292.
  • 7Reis AF, Velho G. Sulfonylurea receptor-I (SUR1): genetic and metabolic evidences for a role in the susceptibility to Type 2 diabetes mellitus. Diabetes Metab, 2002,28 : 14-19.
  • 8Renstrem E, Barg S, Thevened F, et al. Sulfonylurea--mediated stimulation of insulin exocytesis via an ATP--senitive K channel- independent action. Diabetes, 2002,51:33-36.
  • 9Peter P, Frank R, Nick G, et al. Sulfonylurea stimulation of insulin secretion. Diabetes, 2002,51:368-376.
  • 10Korytkowski M, Thomas A, Reid L, et al. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care, 2002,25 : 1607-1611.

同被引文献45

  • 1杨兆军,杨文英,吕肖锋,李全明,李玉凤,郑纪红,王熙然,付佐娣.二甲双胍与格列喹酮或阿卡波糖联合治疗2型糖尿病的临床疗效和安全性比较:多中心、随机、开放、平行分组对照研究[J].中华糖尿病杂志,2009,1(3). 被引量：23
  • 2黄云鸿,蒋筠,吴艺捷,彭永德.磺脲类继发失效糖尿病患者加用胰岛素疗效及胰岛B细胞功能变化[J].中国实用内科杂志,2006,26(5):679-681. 被引量：7
  • 3Holstein A,Patzer OM,Machalke K. Substantial Increase in Incidence of Severe Hypoglycemia Between 1997-2000 and 2007-2010 A German longitudinal population-based study[J].Diabetes Care,2012,(05):972-975.
  • 4Manolopoulos VG,Ragia G,Tavridou A. Pharmacogenomics of oral antidiabetic medications:current data and pharmacoepigenomic perspective[J].Pharmacogenomics,2011,(08):1161-1191.
  • 5Becker ML,Aarnoudse AJ,Newton-Cheh C. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea[J].Pharmacogenetics and Genomics,2008,(07):591-597.doi:10.1097/FPC.0b013e328300e8c5.
  • 6Feng Y,Mao G,Ren X. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients[J].Diabetes Care,2008,(10):1939-1944.doi:10.2337/dc07-2248.
  • 7Holstein A,Hahn M,Stumvol M. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes[J].Hormone and Metabolic Research,2009,(05):387-390.doi:10.1055/s-0029-1192019.
  • 8Hamming K,Soliman D,Matemisz LC. Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K+channel[J].Diabetes,2009,(10):2419-2424.
  • 9Zhang Y,Si D,Chen X,et a1. Influence of CYP2C9 and CYP2C1 9 genetic Polymorphism on pharmacokinetics of gliclazide MR in Chinese subjects[J].British Journal of Clinical Pharmacology,2007,(01):67-74.doi:10.1111/j.1365-2125.2007.02846.x.
  • 10Luo Y,Wang H,Han X. Meta-analysis of the association between SNPs in TCF7L2 and type 2 diabetes in East Asian population[J].Diabetes Research and Clinical Practice,2009,(02):139-146.doi:10.1016/j.diabres.2009.04.024.

引证文献4

二级引证文献89

中华内分泌代谢杂志
2012年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部